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SUmmAry – New-onset diabetes after transplantation (NOdAt) is a frequent and severe com-
plication after renal transplantation. it is diagnosed according to standard criteria for type 2 diabetes. 
risk factors for NOdAt are non-modifiable (non-white ethnicity, older age, genetic predisposition, 
previous glucose intolerance, steroid therapy, male donor, and others) and modifiable (obesity, viral 
infections, and immunosuppressive therapy). glucose control is needed immediately after renal trans-
plantation and after 3, 6, and 12 months and annual glucose control is needed after that period. when 
NOdAt is diagnosed, the primary goal includes lifestyle modification, like a diet with weight loss 
and exercise, and obtaining optimal glucose control to reduce micro- and macrovascular complications 
of diabetes. in order to obtain better glucose control, modification of immunosuppressant therapy is 
also needed, like a reduction of corticosteroid and calcineurin inhibitors and also a conversion of ta-
crolimus to a less glucotoxic agent. Pharmacotherapy includes oral hypoglycemic agents (in most 
cases metformin, sulfonylureas, and dipeptidyl peptidase-4 (dPP-4) inhibitors) and insulin (in most 
cases biphasic insulin several times daily or intensive insulin therapy). finally, metabolic risk factors 
like dyslipidemia and hypertension should also be treated, and a regular annual screening should be 
performed for micro- and macrovascular complications of diabetes.
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Definition
New-onset diabetes after transplantation (NO-
dAt) is a severe and frequent complication after renal 
transplantation. Approximately 15-30% of patients 
with kidney transplants without previous diabetes de-
velop NOdAt during the first year after transplanta-
tion1-3. many more patients after organ transplanta-
tion develop glucose intolerance. before 2003, diabetes 
developed after organ transplantation was usually 
termed as a “posttransplantation diabetes mellitus” be-
cause there was no consensus regarding its definition. 
The requirement of insulin treatment shortly after 
transplantation (usually 30 days) was the clinical defi-
nition of “posttransplantation diabetes mellitus”. 
However, only patients with severe cases of diabetes 
were identified, while patients with other glucose me-
tabolism disorders were not involved. finally, in 2003, 
the international Consensus guidelines advised that 
the diagnosis of NOdAt should be made according 
to the American diabetes Association (AdA) criteria 
for type 2 diabetes4,5
furthermore, in patients with a kidney transplant, 
the plasma glucose level for diagnosing impaired fast-
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ing glucose was set to 5.5 mmol/l6. Although hemo-
globin A1c level ≥ 6.5% is recommended for diagnos-
ing diabetes, it cannot be used as a diagnostic tool in 
the posttransplant period because that period is fre-
quently associated with anemia resulting in false he-
moglobin A1c results7-9. However, it should be stressed 
that the diagnosis of NOdAt does not include pa-
tients with diabetes before transplantation and pa-
tients with transitory hyperglycemia that normalized 
after discharge from the hospital.
Epidemiology
incidence of NOdAt in patients after kidney trans-
plantation depends on diagnostic criteria, immunosup-
pression therapy, and length of follow-up. it is usually 
diagnosed in the first months after transplantation, ac-
companied by immunosuppression therapy in high dos-
es and reaching an incidence of 20%10,11. After that pe-
riod, the incidence of NOdAt decreases with incidence 
stabilizing at around 6% per year, similar to patients in 
the pretransplant period3. moreover, if diabetes is diag-
nosed later in patients after kidney transplantation, it 
can be genuine type 2 diabetes rather than NOdAt.
The prevalence of NOdAt after kidney transplan-
tation is up to 50% and depends on diagnostic criteria, 
immunosuppression regimen, and length of follow-
up12-13. wide variation in prevalence resulted from a 
different criterion for the diagnosis of NOdAt until 
AdA and world Health Organization (wHO) an-
nounced Consensus guidelines in 20034. most studies 
reporting a low incidence of NOdAt do not include 
oral glucose tolerance test (Ogtt) as a diagnostic 
criterion resulting in a significant underestimation of 
incidence14. in addition, hemoglobin A1c testing may 
also modify the incidence of NOdAt since it cannot 
be used as a diagnostic tool in the posttransplant pe-
riod. for example, in a prospective study that included 
122 patients with a renal transplant that had normal 
fasting plasma glucose for over 6 months after trans-
plantation, after Ogtt testing in the same group of 
patients, 18% had impaired fasting glucose, 9% had 
impaired glucose tolerance, and even 10% had diabetes 
mellitus, all defined by wHO criteria15.
Etiology and pathophysiology
metabolic risk factors involved in the pathogenesis 
of type 2 diabetes development also increase the risk of 
NOdAt development in renal transplant recipients. 
table 1summarizes several risk factors for the devel-
opment of NOdAt that can be divided into two ma-
jor categories: those that cannot be modified and those 
that can be potentially modified. The most important 
risk factors that cannot be modified are age over 40 
years, non-white ethnicity, family history of diabetes, 
previously diagnosed glucose intolerance, the presence 
of some specific human leukocyte antigen (HlA) class 
like HlA b42, b27, and A30, history of acute rejec-
tion of renal graft, male donor and polycystic kidneys16. 
As observed in patients with type 2 diabetes, age over 
45 years is the most substantial risk factor for NO-
dAt, and risk for NOdAt incidence in older age in-
creases by almost 50% for every decade increase in 
age17-19. besides, the relative risk of NOdAt increases 
by 90% in patients with renal transplant aged 45-59 
and by 160% in patients with renal transplant aged 
over 60 years compared to the reference (18-44 years). 
Compared to white patients, the relative risk of NO-
dAt is also increased in a specific race, like Hispanic 
patients (35% increased risk) and in black patients 
(32-68% increased risk)20-21. The most important mod-
ifiable risk factors are obesity and other obesity-related 
components of the metabolic syndrome, co-infection 
with cytomegalovirus and hepatitis C, and immuno-
suppressive therapy (calcineurin-inhibitors (particu-
larly tacrolimus), corticosteroids, and sirolimus)16. in 
overweight patients (bmi > 30 kg/m2), the risk of de-
veloping NOdAt in renal transplant patients doubles. 
Positive hepatitis C virus and cytomegalovirus, even in 
those with asymptomatic infection, are independent 
risk factors of NOdAt in renal transplant patients20-22. 
Among modifiable risk factors, the contribution of 
immunosuppressive agents to NOdAt development 
is predominant4,16,23. The role of corticosteroids in the 
development of NOdAt is dose-dependent, which 
was first described in 1964 in patients with renal trans-
plant24.
The etiology of NOdAt is complex and not fully 
understood, but insulin deficiency, insulin resistance, 
and impaired beta cell insulin secretion are key under-
lying metabolic abnormalities25. insulin resistance and 
secretion are suppressed by immunosuppressive medi-
cations, particularly calcineurin inhibitors and gluco-
corticoids26. besides inhibition of t lymphocyte acti-
vation via a connection with intracellular target pro-
teins, immunosuppressive medications also cause a 
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defect in beta cell insulin secretion and increase pe-
ripheral insulin resistance25. Corticosteroids are basic 
post-transplant immunosuppressive medication and a 
part of the majority of the therapies scheme. in renal 
transplant recipients treated with corticosteroids, the 
risk of NOdAt is related both to the duration of 
therapy and used dose17. The most important effect of 
corticosteroids is the increase in peripheral insulin re-
sistance. Consequently, corticosteroids increase hepat-
ic gluconeogenesis and glucose secretion and increase 
insulin resistace27,28. Corticosteroids also suppress be-
ta-cell insulin secretion and decrease glycogenesis, in-
crease fasting and postprandial glucose level and in-
duce islet cell apoptosis at higher doses29-31. High 
doses of corticosteroids during the first year after renal 
transplantation, particularly in patients with acute 
graft rejection, significantly increase the risk of devel-
opment of NOdAt. for example, in patients treated 
with corticosteroids, a 0.01 mg/kg higher predniso-
lone daily dose increase risk of developing NOdAt by 
5%32. in contrast, a progressive decrease in predniso-
lone dose during the first 12 months after renal trans-
plantation significantly improves glucose control33.
tacrolimus and cyclosporine are calcineurin-inhib-
itor drugs that are widely used in patients with renal 
transplantation and in most cases, patients are treated 
with one or the other drug as part of their immuno-
suppressive combination. both drugs impair insulin 
release and insulin sensitivity, which are the most im-
portant mechanisms for calcineurin-inhibitor induced 
NOdAt. However, the risk of NOdAt development 
is about 50% higher with tacrolimus compared to cy-
closporine and, compared to corticosteroids, it seems 
that the effect on NOdAt is not related to used 
dose2,3,34-36. tacrolimus is the preferred calcineurin-in-
hibitor drug because it has superior efficacy and safe-
ty37. The main pathophysiological disorders that cause 
hyperglycemia in patients with renal transplantation 
are apoptosis of beta-cell and insulin resistance. in a 
beta-cell, calcineurin is a calmodulin-dependent ser-
ine/threonine phosphatase that consists of two sub-
units, both of which are required for its function. in 
addition, calcium influx activates calcineurin and in-
teracts with proteins that are involved in beta-cell 
function, proliferation, and maturation38. treatment 
with calcineurin-inhibitor drugs reversibly suppresses 
the secretion of insulin, attacking insulin mrNA tran-
scription39. At peripheral muscles, calcineurin is in-
volved in gene transcription that improves insulin sen-
sitivity, and calcineurin deficiency increases insulin re-
sistance in muscles. in addition, calcineurin-inhibitors 
also reduce glucose transporter type 4 (glUt-4) re-
ceptor molecules at the cell membrane of peripheral 
tissues (muscle and adipose tissue), blocking glucose 
entry into the cell cytoplasm40,41. tacrolimus also sup-
presses glucose-induced insulin release from beta-cell 
via reduced glucokinase activity42. At the microscopic 
level, treatment with calcineurin-inhibitors results in 
cytoplasmic swelling, altered insulin staining, and vac-
uolization43. in a prospective study that included over 
8000 patients with renal transplantation, treatment 
with tacrolimus was associated with a significantly 
higher incidence of NOdAt compared to cyclospo-
rin44. moreover, the risk for NOdAt is increased more 
than two-fold at the highest dosages of tacrolimus, and 
even at the lowest dosages of tacrolimus, the risk for 
NOdAt is increased by over 28%. The diabetogenic 
effect of tacrolimus is further potentiated with increas-
ing steroid dosages, so the patients who receive >0.75 
mg/kg per day have the highest risk for NOdAt. 
Compared to tacrolimus, a higher steroid dose does 
not increase the risk for NOdAt in patients treated 
with cyclosporine.
Sirolimus is an immunosuppressive agent also used 
in patients with renal transplantation that increases 
the risk of NOdAt. However, it seems that the risk of 
NOdAt in patients on sirolimus therapy is mainly 
due to its combination with calcineurin-inhibitors, al-
though extensive database studies and single-center 
reviews suggest that sirolimus itself is also a risk factor 
for NOdAt45,46. The diabetogenic activity of sirolimus 
is mediated by hypertriglyceridemia and insulin resis-
tance47. Since sirolimus is neutral with respect to NO-
dAt compared to calcineurin-inhibitors, conversion 
from calcineurin-inhibitors to sirolimus may decrease 
the risk of NOdAt17,48.
in order to improve glucose control in patients 
with established NOdAt, but also to decrease the risk 
for NOdAt development, AdA suggests an algo-
rithm for immunosuppression management in pa-
tients with renal transplantation10. in patients with a 
high risk of NOdAt development but with low im-
munological risk, the first choice might be the cyclo-
sporine-glucocorticoid combination, and in the case of 
NOdAt development or inadequate glucose control, 
a switch to belatacept is indicated with glucocorticoid 
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reduction. in patients with high immunological risk, 
the first choice is tacrolimus-glucocorticoid combina-
tion37,49. in the case of NOdAt development or inad-
equate glucose control, a reduction of tacrolimus and 
glucocorticoid should be made. finally, if there is no 
improvement in glucose control 6 months after trans-
plantation and 3 months of minimal glucocorticoid 
dose, a switch to cyclosporine is considered in patients 
with high immunological risk, and in patients with 
low immunological risk, a therapy with belatacept 
should be considered.
NOdAt in patients with renal transplantation 
negatively affects the survival of graft and patient. in 
patients with renal transplantation but without diabe-
tes, the risk of cardiovascular disease is increased two-
fold compared to the general population, and that risk 
is additionally increased after the development of NO-
dAt50,51. Therefore, patients with renal transplanta-
tion and NOdAt have a significantly increased risk of 
developing the cardiovascular disease but also de-
creased survival rate compared to patients without 
NOdAt52. Patients with renal transplantation and 
NOdAt have several risk factors that increase the risk 
of cardiovascular disease like hyperinsulinemia, glu-
cose intolerance, hypertension, dyslipidemia, and insu-
lin resistance. besides increased cardiovascular risk, 
patients with renal transplantation and NOdAt have 
an increased risk of infections and sepsis. After organ 
transplantation, the survival rate of patients with NO-
dAt is reduced by 3 years compared to patients with-
out NOdAt53. NOdAt in renal transplant recipients 
also has adverse effects on graft function and survival54. 
Proposed mechanisms include a higher risk of micro-
vascular complication (particularly diabetic nephropa-
thy), hypertension, increased risk of urinary infections, 
and low immunosuppressant doses4.
Diagnosis
A precise incidence of NOdAt has been difficult 
to estimate in years before 2003 because of different 
definitions and diagnostic criteria of NOdAt. de 
novo diabetes after organ transplantation was usually 
termed as a “posttransplantation diabetes mellitus” 
and diagnosed as random plasma glucose over 11.1 
mmol/l, or fasting plasma glucose over 7.7 mmol/l 
or treatment of hyperglycemia with oral agent or insu-
lin in the period after organ transplantation. finally, in 
2003, international Consensus guidelines and AdA 
declare that the diagnosis of NOdAt should be the 
same as the criteria for diagnosing type 2 diabetes4,5. 
All patients in the pre-transplant baseline evaluation 
should perform standard Ogtt according to wHO 
procedures with 75 g of glucose melted in water4. in 
addition, in the pretransplant management and evalu-
ation period, medical documentation of patients and 
family glucose history should be included55. Patients 
with abnormal Ogtt before transplantation indicat-
ing impair glucose tolerance should be screened once a 
year4. Patients with Ogtt suggesting glucose intol-
erance or overt diabetes before transplantation must be 
educated about diet and weight control, lifestyle mod-
ifications with exercise, and also treated with adequate 
therapy (oral hypoglycemic agents or insulin therapy). 
After renal transplantation, patients must control fast-
ing plasma glucose at regular periods (0, 3, 6, and 12 
months after transplantation). After that time, one-
yearly testing of fasting plasma glucose should be per-
formed (figure 1)4. if fasting plasma glucose suggests 
glucose intolerance or overt diabetes test is repeated 
two times, it is important that the sample be measured 
after an overnight fast (8-12 hour). However, the most 
sensitive test for diagnosis of diabetes is a standard 
Table 1: New-onset diabetes after kidney transplantation: risk factors
Non-modifiable risk factors modifiable risk factors
- Older age
- Non-white race
- genetic predisposition (HlA A28, A30, b27, bw42)
- Polycystic kidney disease
- Previous glucose intolerance
- Previous steroid therapy
- male donor
- deceased donor
- diabetes in parents and/or relatives
-  Obesity and metabolic syndrome
-  low physical activity
-  Viral infection (hepatitis C, cytomegalovirus)
-  Corticosteroids: ↑ gluconeogenesis, ↑ insulin resistance,  
↓ secretion, ↓ beta-cell function
-  Calcineurin-inhibitors: ↓ insulin release, ↓ insulin 
sensitivity, ↓ glucose uptake, ↓ beta-cell function,  
↓ beta-cell proliferation, ↓ beta-cell maturation
-  Sirolimus: ↑ triglyceridemia, ↑ insulin resistance
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Ogtt with 75g glucose melted in water, but that is 
not practical for routine use25. The diagnosis of diabe-
tes should not be relied on hemoglobin A1c level or 
capillary blood glucose in wait-listed patients as well 
as after transplantation because in that period anemia 
is a common finding resulting in misleading hemoglo-
bin A1c results7-9. Urine testing may detect positive 
ketones that are strong evidence not only for hypergly-
Figure 1: Algorithm for the diagnosis of diabetes in patients before and after kidney transplantation
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cemia but also for patients that have insulin deficiency 
and must be treated with insulin therapy. Patients with 
renal transplantation and NOdAt should be checked 
for hemoglobin A1c every 3 months and even more 
often fasting plasma glucose in the early posttrans-
plant period.
After the diagnosis of NOdAt, patients must be 
educated about diet and weight control, lifestyle mod-
ifications with exercise, and regular monitoring of 
blood glucose with appropriate follow-up, in order to 
reduce the risk of the short- and long-term complica-
tions of diabetes. in addition, strict control and treat-
ment of other metabolic disorders associated with dia-
betes like hypertension and dyslipidemia are also 
needed56. Corticosteroid and calcineurin inhibitors 
reduction in the early posttransplant period will im-
prove glucose control, but this decision should be made 
by transplant nephrologist 4,25,57. if possible, conversion 
of tacrolimus to less glucotoxic agents like cyclosporin 
or mycophenolic acid can reduce hyperglycemia58,59. 
Patients with NOdAt must be treated according to 
the AdA guidelines for managing patients with type 2 
diabetes because there are no studies conducted spe-
cifically in patients with transplantation4. The primary 
goal and first step are maintenance of ideal body 
weight through dietary modification and also in-
creased physical activity, similar to the treatment of 
patients with type 2 diabetes4. glucose monitoring in 
patients with NOdAt should be checked with hemo-
globin A1c initially every 3 months and also with fast-
ing plasma glucose at each visit. The hemoglobin be-
low 7% should be considered a reasonable goal, al-
though there is no study evaluating specific cut-off for 
hemoglobin A1c in NOdAt patients4. However, the 
period after kidney transplantation is frequently asso-
ciated with anemia resulting in misleading hemoglo-
bin A1c results7-9. besides glucose control, hyperten-
sion and dyslipidemia should also be treated because, 
in connection with diabetes, these are major contribu-
tors to cardiovascular disease, but also immunosup-
pressive therapy may further aggravate hypertension 
and dyslipidemia60,61. According to AdA guidelines, 
the reference range for blood pressure and serum lipids 
in patients with NOdAt is the same as for patients 
with type 2 diabetes. fluvastatin and pravastatin have 
the lowest drug interactions compared to other 
statins62. Antihypertensive therapy should include 
treatment with angiotensin-converting enzyme (ACe) 
inhibitors and angiotensin ii receptor blockers (Arb).
Adoption of lifestyle modification like diet and ex-
ercise with weight loss can improve glycemic control 
over 6 months63. if hemoglobin A1c rises over 6.5%, 
then pharmacotherapy must be started or changed. 
The choice between an appropriate oral agent or insu-
lin depends on the severity of hyperglycemia, timing of 
developed hyperglycemia after transplantation, and 
comorbidities23. early after transplantation, when pa-
tients are treated with high doses of immunosuppres-
sant and graft function is not yet fully established, pa-
tients are usually treated with insulin therapy48. bipha-
sic insulin several times daily (premix insulin) is typi-
cally required in the early post-transplant period 
because corticosteroids are usually given in the morn-
ing, resulting in high glucose levels in the afternoon. in 
case of persistent hyperglycemia with biphasic insulin 
several times daily, intensive insulin therapy is needed. 
treatment with a combination of long-acting insulin 
and oral hypoglycemic agent, often used in patients 
with type 2 diabetes, is not effective in patients with 
NOdAt.
The selection of an optimal oral hypoglycemic 
agent is usually determined with a glomerular filtra-
tion rate. in patients with renal transplantation and 
NOdAt, no oral hypoglycemic agent is contraindi-
cated and all oral hypoglycemic agents can combine 
with immunosuppressive drugs, according to glomeru-
lar filtration rate. metformin, the first choice and gold 
standard treatment in patients with type 2 diabetes, is 
usually prescribed as a first-line option in renal trans-
plant recipients with NOdAt because metformin im-
proves insulin sensitivity often present in patients with 
NOdAt and can be safely used if glomerular filtra-
tion rate is over 45 ml/min64. Sulfonylureas are also 
widely used in renal transplant recipients with NO-
dAt because they are the most powerful oral hypo-
glycemic agent in reducing hemoglobin A1c. in addi-
tion, newer and mostly used sulfonylurea gliclazide 
can be safely used even in those with chronic kidney 
disease. However, they may exacerbate weight gain in 
the period after renal transplantation and may increase 
the serum concentration of cyclosporine, and the risk 
of hypoglycemia is also increased14. besides long-act-
ing sulfonylureas like gliclazide, short-acting sulfonyl-
urea repaglinide can be safely used in patients with 
renal transplantation and NOdAt65. Thiazolidinedio-
nes like metformin improve insulin sensitivity often 
present in patients with NOdAt and improve glucose 
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tolerance and endothelial function66. However, since 
treatment with thiazolidinediones increases the risk 
for heart failure and cyclosporine may promote sodi-
um retention and many patients after renal transplan-
tation are already at high risk of heart failure, thiazoli-
dinediones are usually avoided in the majority of pa-
tients with NOdAt. dipeptidyl peptidase-4 (dPP-4) 
inhibitors are safe and effective in patients with renal 
transplantation and NOdAt67,68. These drugs inhibit 
the dPP-4 enzyme and consequently increase pancre-
atic insulin secretion and decrease pancreatic glucagon 
secretion. There is no risk of weight gain and hypogly-
cemia. Sodium-glucose cotransporter (Sglt) 2 in-
hibitors inhibit renal glucose reabsorption in the prox-
imal tubule increasing glucosuria. besides, better glu-
cose control therapy with Sglt-2 inhibitors also re-
sults in weight loss without risk of hypoglycemia. 
However, Sglt-2 inhibitors cannot be used in case of 
reduced renal function. in addition, since the risk of 
urinary and genital infection is significantly increased, 
Sglt-2 inhibitors are usually not used in patients 
with renal transplantation and NOdAt69. if glucose 
control is inadequate with a single oral hypoglycemic 
agent, a combination of two or three drugs with differ-
ent mechanisms of action are reasonable before start-
ing with insulin therapy. in patients with marked hy-
perglycemia, infection, and impaired graft function or 
with high doses of immunosuppressive drugs, initia-
tion of insulin therapy should not be delayed. more-
over, early initiation of insulin therapy in the period 
after transplantation can preserve beta-cell function 
and decreases NOdAt incidence after renal trans-
plantation70.
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Sažetak
NOVONAStAlA ŠeĆerNA bOleSt NAkON trANSPlANtACiJe bUbregA:  
diJAgNOZA, riZiČNi fAktOri i liJeČeNJe
T. Bulum, I. Prkačin i L. Duvnjak
Šećerna bolest nakon transplantacije (NOdAt) je česta i ozbiljna komplikacija nakon transplantacije bubrega. dijagno-
sticira se na temelju kriterija za dijagnozu šećerne bolesti tipa 2. rizične faktore za razvoj NOdAt-a dijelimo na one na koje 
ne možemo utjecati (dob, nebijela rasa, genetska predispozicija, prethodna intolerancija glukoze ili terapija kortikosteroidi-
ma, muški donor i ostali) i one na koje možemo utjecati (debljina, virusna infekcija, imunosupresivna terapija). Nakon tran-
splantacije bubrega glikemija natašte se treba određivati svaka tri mjeseca tijekom prve godine, a nakon toga jedanput godiš-
nje. Ukoliko se dijagnosticira NOdAt potrebna je promjena životnih navika (kontrola težine, dijeta, tjelovježba), i redovita 
kontrola glikemije s ciljem sprječavanja nastanka komplikacija šećerne bolesti. Smanjenje doze kortikosteroida smanjuje hi-
perglikemiju kao i smanjenje doze kalcineurinskih inhibitora i konverzija takrolimusa u druge imunosupresivne lijekove. 
farmakoterapija uključuje liječenje oralnim hipoglikemijskim lijekovima (najčešće metformin, preparati sulfonilureje te in-
hibitori dipeptidil peptidaze-4 (dPP-4)) te inzulinom (najčešće predmiješanim inzulinom u više dnevnih doza ili intenzivi-
ranom inzulinskom terapijom). Potrebno je liječenje i ostalih poremećaja u sklopu šećerne bolesti kao što su hipertenzija i 
hiperlipidemija te godišnji uvid u kronične komplikacije šećerne bolesti (retinopatija, nefropatija, neuropatija, periferna arte-
rijska bolest te kardiovaskularna bolest) s ciljem očuvanja kvalitete života.
ključne riječi: novonastala šećerna bolest nakon transplantacije organa (NODAT), transplantacija bubrega, imunosupresivni 
lijekovi, liječenje šećerne bolesti
